ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Desensitization Protocol Consisting of High-Dose Intravenous Immunoglobulin, Plasmapheresis, and Rituximab in Highly Sensitized Kidney Transplant Recipients

M. Okada, T. Hiramitsu, T. Tomosugi, K. Futamura, S. Narumi, N. Goto, Y. Watarai

Nagoya Daini Red Cross Hospital, Nagoya, Japan

Meeting: 2022 American Transplant Congress

Abstract number: 1028

Keywords: Flowcytometry crossmatching, HLA antibodies, Immunoglobulins (Ig), Kidney transplantation

Topic: Clinical Science » Kidney » 36 - Kidney Immunosuppression: Desensitization

Session Information

Session Name: Kidney Immunosuppression: Desensitization

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: In HLA incompatible kidney transplantation, donor-specific HLA antibody often causes antibody-mediated rejection (AMR). To prevent AMR, we adopted a preoperative desensitization protocol including high-dose intravenous immunoglobulin (IVIG), plasmapheresis (PEX) and rituximab in sensitized recipients with positive flow cytometry crossmatch (FCXM).

*Methods: Patients who received the desensitization therapy with IVIG, PEX and rituximab for HLA incompatible living donor kidney transplantation (LDKT) since 2014 were included. We retrospectively investigated the patient background, clinical courses, DSA levels, and graft function.

*Results: Among the 11 HLA incompatible LDKT, AMR was revealed in 2 cases (18.2%) within 1 month after transplantation. There was no grafts loss during an average of 2.6-year follow-up. Average graft function was acceptable, with a serum creatinine level of 1.3 ± 0.7 mg/dL.

*Conclusions: The desensitization protocol including high-dose IVIG, PEX and rituximab is effective for achieving successful transplant outcomes in HLA incompatible LDKT with positive FCXM, which can spare aggressive treatments, such as C5 inhibitors, proteasome inhibitors, or imlifidase.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Okada M, Hiramitsu T, Tomosugi T, Futamura K, Narumi S, Goto N, Watarai Y. Desensitization Protocol Consisting of High-Dose Intravenous Immunoglobulin, Plasmapheresis, and Rituximab in Highly Sensitized Kidney Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/desensitization-protocol-consisting-of-high-dose-intravenous-immunoglobulin-plasmapheresis-and-rituximab-in-highly-sensitized-kidney-transplant-recipients/. Accessed May 25, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences